{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:19:14Z","timestamp":1792887554858,"version":"4.5.0"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jconrel.2023.09.003","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T15:30:40Z","timestamp":1695310240000},"page":"12-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":131,"special_numbering":"C","title":["Accelerated blood clearance of PEGylated nanoparticles induced by PEG-based pharmaceutical excipients"],"prefix":"10.1016","volume":"363","author":[{"given":"Guifeng","family":"Miao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuejian","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keren","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guozhu","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2023.09.003_bb0005","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2023.09.003_bb0010","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1146\/annurev-pharmtox-010611-134623","article-title":"Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective","volume":"52","author":"Moghimi","year":"2012","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.jconrel.2023.09.003_bb0015","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/s41578-021-00315-x","article-title":"Multifunctional biomolecule nanostructures for cancer therapy","volume":"6","author":"Wang","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.jconrel.2023.09.003_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.jconrel.2023.09.003_bb0025","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2217\/nnm.11.19","article-title":"Nanoparticle PEGylation for imaging and therapy","volume":"6","author":"Jokerst","year":"2011","journal-title":"Nanomed."},{"key":"10.1016\/j.jconrel.2023.09.003_bb0030","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.apsb.2022.05.010","article-title":"Macrophage-evading and tumor-specific apoptosis inducing nanoparticles for targeted cancer therapy","volume":"13","author":"Liu","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2023.09.003_bb0035","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0169-409X(95)00039-A","article-title":"Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system","volume":"17","author":"Storm","year":"1995","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2023.09.003_bb0040","doi-asserted-by":"crossref","first-page":"8178","DOI":"10.1021\/la060951b","article-title":"Macrophage uptake of core\u2212 shell nanoparticles surface modified with poly (ethylene glycol)","volume":"22","author":"Zahr","year":"2006","journal-title":"Langmuir"},{"key":"10.1016\/j.jconrel.2023.09.003_bb0045","doi-asserted-by":"crossref","first-page":"13557","DOI":"10.1021\/jacs.1c03943","article-title":"Formulation of metal\u2013organic framework-based drug carriers by controlled coordination of methoxy PEG phosphate: boosting colloidal stability and redispersibility","volume":"143","author":"Chen","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2023.09.003_bb0050","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1016\/j.apsb.2021.11.016","article-title":"The long-circulating effect of pegylated nanoparticles revisited via simultaneous monitoring of both the drug payloads and nanocarriers","volume":"12","author":"Fan","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2023.09.003_bb0055","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nrd2591","article-title":"Strategies in the design of nanoparticles for therapeutic applications","volume":"9","author":"Petros","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2023.09.003_bb0060","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","article-title":"PEGylation as a strategy for improving nanoparticle-based drug and gene delivery","volume":"99","author":"Suk","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2023.09.003_bb0065","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S1359-6446(05)03575-0","article-title":"PEGylation, successful approach to drug delivery","volume":"10","author":"Veronese","year":"2005","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2023.09.003_bb0070","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae\u2014the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.09.003_bb0075","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.addr.2020.07.024","article-title":"Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals","volume":"154","author":"Kozma","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2023.09.003_bb0080","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0022-3565(24)35391-1","article-title":"Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes","volume":"292","author":"Dams","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2023.09.003_bb0085","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jconrel.2006.08.017","article-title":"Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection","volume":"115","author":"Ishida","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.09.003_bb0090","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jconrel.2013.07.026","article-title":"The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage","volume":"172","author":"Lila","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.09.003_bb0095","doi-asserted-by":"crossref","first-page":"14022","DOI":"10.1021\/acsnano.1c05922","article-title":"Polyethylene glycol immunogenicity: theoretical, clinical, and practical aspects of anti-polyethylene glycol antibodies","volume":"15","author":"Chen","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2023.09.003_bb0100","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/wnan.1339","article-title":"Anti-PEG immunity: emergence, characteristics, and unaddressed questions","volume":"7","author":"Yang","year":"2015","journal-title":"Wires. Nanomed. Nanobi."},{"key":"10.1016\/j.jconrel.2023.09.003_bb0105","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jconrel.2007.05.015","article-title":"PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner","volume":"122","author":"Ishida","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.09.003_bb0110","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.nantod.2014.02.004","article-title":"Poly (carboxybetaine) nanomaterials enable long circulation and prevent polymer-specific antibody production","volume":"9","author":"Yang","year":"2014","journal-title":"Nano Today"},{"key":"10.1016\/j.jconrel.2023.09.003_bb0115","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/cncr.22739","article-title":"Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients","volume":"110","author":"Armstrong","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2023.09.003_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar4500","article-title":"Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients","volume":"16","author":"Hershfield","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jconrel.2023.09.003_bb0125","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0140-6736(13)61841-3","article-title":"Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial","volume":"384","author":"Longo","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2023.09.003_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/17425240802650568","article-title":"PEG-modified biopharmaceuticals","volume":"6","author":"Bailon","year":"2009","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2023.09.003_bb0135","first-page":"1","article-title":"Clinical relevance of pre-existing and treatment-induced anti-poly (ethylene glycol) antibodies","author":"Freire Haddad","year":"2021","journal-title":"Regen. Eng. Transl. Med."},{"key":"10.1016\/j.jconrel.2023.09.003_bb0140","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jconrel.2016.06.040","article-title":"Anti-PEG antibodies in the clinic: current issues and beyond PEGylation","volume":"244","author":"Zhang","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.09.003_bb0145","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000233512","article-title":"Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors","volume":"74","author":"Richter","year":"1984","journal-title":"Int. Arch. Allergy Appl. Immunol."},{"key":"10.1016\/j.jconrel.2023.09.003_bb0150","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.tmrv.2004.06.005","article-title":"Progress in modulating the RBC membrane to produce transfusable universal\/stealth donor RBCs","volume":"18","author":"Garratty","year":"2004","journal-title":"Transfus. Med. Rev."},{"key":"10.1016\/j.jconrel.2023.09.003_bb0155","doi-asserted-by":"crossref","first-page":"10661","DOI":"10.1021\/acs.analchem.6b03109","article-title":"Measurement of pre-existing IgG and IgM antibodies against polyethylene glycol in healthy individuals","volume":"88","author":"Chen","year":"2016","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jconrel.2023.09.003_bb0160","doi-asserted-by":"crossref","first-page":"11804","DOI":"10.1021\/acs.analchem.6b03437","article-title":"Analysis of pre-existing IgG and IgM antibodies against polyethylene glycol (PEG) in the general population","volume":"88","author":"Yang","year":"2016","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jconrel.2023.09.003_bb0165","doi-asserted-by":"crossref","first-page":"112669","DOI":"10.1016\/j.jim.2019.112669","article-title":"A generic method for the detection of polyethylene glycol specific IgG and IgM antibodies in human serum","volume":"474","author":"Ehlinger","year":"2019","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jconrel.2023.09.003_bb0170","doi-asserted-by":"crossref","first-page":"11769","DOI":"10.1021\/acsnano.2c04543","article-title":"Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine","volume":"16","author":"Ju","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2023.09.003_bb0175","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1021\/acs.molpharmaceut.0c00366","article-title":"Impact of pre-existing or induced anti-PEG IgM on the pharmacokinetics of Peginterferon alfa-2a (Pegasys) in mice","volume":"17","author":"Elsadek","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2023.09.003_bb0180","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.7150\/thno.22164","article-title":"Pre-existing anti-polyethylene glycol antibody reduces the therapeutic efficacy and pharmacokinetics of PEGylated liposomes","volume":"8","author":"Hsieh","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2023.09.003_bb0185","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3324\/haematol.2020.258525","article-title":"Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia","volume":"107","author":"Khalil","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.jconrel.2023.09.003_bb0190","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.jaci.2016.04.058","article-title":"Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer","volume":"138","author":"Povsic","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jconrel.2023.09.003_bb0195","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jconrel.2021.11.042","article-title":"Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement","volume":"341","author":"Senti","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.09.003_bb0200","doi-asserted-by":"crossref","first-page":"105","DOI":"10.5487\/TR.2015.31.2.105","article-title":"Safety evaluation of polyethylene glycol (PEG) compounds for cosmetic use","volume":"31","author":"Jang","year":"2015","journal-title":"Toxicol. Res."},{"key":"10.1016\/j.jconrel.2023.09.003_bb0205","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.2165\/00003495-200464150-00009","article-title":"Oral sodium phosphate solution: a review of its use as a colorectal cleanser","volume":"64","author":"Curran","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2023.09.003_bb0210","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/17425247.2016.1182485","article-title":"Polyethylene glycol (PEG): a versatile polymer for pharmaceutical applications","volume":"13","author":"D\u2019souza","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2023.09.003_bb0215","doi-asserted-by":"crossref","first-page":"6288","DOI":"10.1002\/anie.200902672","article-title":"Poly (ethylene glycol) in drug delivery: pros and cons as well as potential alternatives","volume":"49","author":"Knop","year":"2010","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jconrel.2023.09.003_bb0220","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1023\/B:PHAM.0000016235.32639.23","article-title":"Solubilizing excipients in oral and injectable formulations","volume":"21","author":"Strickley","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2023.09.003_bb0225","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40265-021-01480-7","article-title":"BNT162b2 mRNA COVID-19 vaccine: first approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2023.09.003_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120586","article-title":"mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability","volume":"601","author":"Schoenmaker","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.09.003_bb0235","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41577-022-00825-x","article-title":"Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines","volume":"23","author":"Ju","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2023.09.003_bb0240","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jconrel.2023.01.012","article-title":"Investigation of anti-PEG antibody response to PEG-containing cosmetic products in mice","volume":"354","author":"Ibrahim","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.09.003_bb0245","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1517\/17425247.2013.796360","article-title":"Applications of poloxamers in ophthalmic pharmaceutical formulations: an overview","volume":"10","author":"Almeida","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2023.09.003_bb0250","first-page":"159","article-title":"Poloxamer: a novel functional molecule for drug delivery and gene therapy","volume":"5","author":"Devi","year":"2013","journal-title":"J. Pharm. Sci. Res."},{"key":"10.1016\/j.jconrel.2023.09.003_bb0255","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1007\/s11095-006-9104-4","article-title":"A review of poloxamer 407 pharmaceutical and pharmacological characteristics","volume":"23","author":"Dumortier","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2023.09.003_bb0260","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3390\/pharmaceutics10030159","article-title":"Mucosal applications of poloxamer 407-based hydrogels: an overview","volume":"10","author":"Giuliano","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2023.09.003_bb0265","first-page":"299","article-title":"Poloxamers: a pharmaceutical excipients with therapeutic behaviors","volume":"1","author":"Patel","year":"2009","journal-title":"Int. J. Pharm.Tech. Res."},{"key":"10.1016\/j.jconrel.2023.09.003_bb0270","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3390\/pharmaceutics11120671","article-title":"Poloxamer hydrogels for biomedical applications","volume":"11","author":"Russo","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2023.09.003_bb0275","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.drudis.2019.05.036","article-title":"Poloxamer-based in situ gelling thermoresponsive systems for ocular drug delivery applications","volume":"24","author":"Soliman","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2023.09.003_bb0280","article-title":"Detection of endotoxin in nano-formulations using limulus amoebocyte lysate (LAL) assays","volume":"143","author":"Neun","year":"2019","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.jconrel.2023.09.003_bb0285","series-title":"Pharmacopoeia","author":"U. S. Bacterial Endotoxins Test","year":"2011"},{"key":"10.1016\/j.jconrel.2023.09.003_bb0290","doi-asserted-by":"crossref","first-page":"115991","DOI":"10.1016\/j.trac.2020.115991","article-title":"A review on various analytical methods for determination of anthracyclines and their metabolites as anti\u2013cancer chemotherapy drugs in different matrices over the last four decades","volume":"130","author":"Pashaei","year":"2020","journal-title":"Trends Anal. Chem."},{"key":"10.1016\/j.jconrel.2023.09.003_bb0295","doi-asserted-by":"crossref","first-page":"10980","DOI":"10.1073\/pnas.1106634108","article-title":"Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform","volume":"108","author":"Hu","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2023.09.003_bb0300","doi-asserted-by":"crossref","first-page":"10130","DOI":"10.1021\/acsnano.8b04947","article-title":"Dense and dynamic polyethylene glycol shells cloak nanoparticles from uptake by liver endothelial cells for long blood circulation","volume":"12","author":"Zhou","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2023.09.003_bb0305","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1021\/acs.molpharmaceut.5b00144","article-title":"Anti-PEG IgM is a major contributor to the accelerated blood clearance of polyethylene glycol-conjugated protein","volume":"12","author":"Mima","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2023.09.003_bb0310","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1590\/S0074-02762000000200014","article-title":"A simple method for human peripheral blood monocyte isolation","volume":"95","author":"De Almeida","year":"2000","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.jconrel.2023.09.003_bb0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-022X(00)00066-X","article-title":"Fractionation of cells and subcellular particles with Percoll","volume":"44","author":"Pertoft","year":"2000","journal-title":"J. Biochem. Biophys. Methods"},{"key":"10.1016\/j.jconrel.2023.09.003_bb0320","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1021\/nn2000756","article-title":"Differential uptake of functionalized polystyrene nanoparticles by human macrophages and a monocytic cell line","volume":"5","author":"Lunov","year":"2011","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2023.09.003_bb0325","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1189\/jlb.1104636","article-title":"The expression and roles of toll-like receptors in the biology of the human neutrophil","volume":"77","author":"Parker","year":"2005","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.jconrel.2023.09.003_bb0330","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2165\/00003495-199700544-00007","article-title":"Safety aspects of pegylated liposomal doxorubicin in patients with cancer","volume":"54","author":"Alberts","year":"1997","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2023.09.003_bb0335","doi-asserted-by":"crossref","first-page":"7808","DOI":"10.1021\/acsnano.9b07218","article-title":"Premature drug release from polyethylene glycol (PEG)-coated liposomal doxorubicin via formation of the membrane attack complex","volume":"14","author":"Chen","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2023.09.003_bb0340","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ijpharm.2016.02.027","article-title":"In situ gelling systems based on Pluronic F127\/Pluronic F68 formulations for ocular drug delivery","volume":"502","author":"Al Khateb","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.09.003_bb0345","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.apsb.2017.03.003","article-title":"In vivo retention of poloxamer-based in situ hydrogels for vaginal application in mouse and rat models","volume":"7","author":"Liu","year":"2017","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2023.09.003_bb0350","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1208\/s12248-012-9340-y","article-title":"Immunogenicity to therapeutic proteins: impact on PK\/PD and efficacy","volume":"14","author":"Chirmule","year":"2012","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2023.09.003_bb0355","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1023\/B:PHAM.0000029275.41323.a6","article-title":"Structure-immunogenicity relationships of therapeutic proteins","volume":"21","author":"Hermeling","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2023.09.003_bb0360","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1021\/acs.molpharmaceut.7b00939","article-title":"Poloxamer 407\/TPGS mixed micelles as promising carriers for cyclosporine ocular delivery","volume":"15","author":"Grimaudo","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2023.09.003_bb0365","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.bbadis.2004.02.005","article-title":"Causative factors behind poloxamer 188 (Pluronic F68, FlocorTM)-induced complement activation in human sera: a protective role against poloxamer-mediated complement activation by elevated serum lipoprotein levels","volume":"1689","author":"Moghimi","year":"2004","journal-title":"BBA-Mol. Basis Dis."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923005898?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923005898?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:45:32Z","timestamp":1759164332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365923005898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":73,"alternative-id":["S0168365923005898"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.09.003","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Accelerated blood clearance of PEGylated nanoparticles induced by PEG-based pharmaceutical excipients","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}